Enterococcal Superinfection and Colonization After Therapy with Moxalactam, a New Broad-Spectrum Antibiotic
Authors: VICTOR L. YU
Journal: Annals of Internal Medicine (1981)

Brief Reports1 June 1981Enterococcal Superinfection and Colonization After Therapy with Moxalactam, a New Broad-Spectrum AntibioticVICTOR L. YU, M.D.VICTOR L. YU, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-6-784 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMoxalactam is a new broad-spectrum antimicrobial drug that is structurally related to the cephalosporins (1). Its favorable pharmacokinetic properties allow it to be administered at 8-hour intervals (2), and unlike other cephalosporins, it reaches the cerebrospinal fluid in therapeutic concentrations (3). However, its major attraction is its effectiveness in vitro against many bacterial pathogens. It is active against the usual pathogenic gram-positive cocci (streptococci, pneumococci, staphylococci) as well as the Enterobacteriaceae (1, 4). Moreover, it is active in vitro against anaerobes (includingBacteroides fragilis) as well asHaemophilus influenzae(including ampicillin-resistant strains) andPseudomonas aeruginosa(4-6). No other commercially available...References1. NEUASWAPOKEEFUASWAPOKEE HNKP. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other β-lactam compounds. Antimicrob Agents Chemother. 1979;16:141-9. CrossrefMedlineGoogle Scholar2. PARSONSROMANOLEVISON JJM. Pharmacology of a new 1-oxa-β-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980;17:226-8. CrossrefMedlineGoogle Scholar3. LANDESMANCORRADOCHERUBINGOMBERTCLERI SMCMD. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid: implications for therapy of gram-negative bacillary meningitis. Am J Med. 1980;69:92-8. CrossrefMedlineGoogle Scholar4. BARZATALLYJACOBUSGORBACH MFNS. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979;16:287-92. CrossrefMedlineGoogle Scholar5. MASONKAPLANANDERSONHINDSFEIGIN ESDDR. In vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillin. Antimicrob Agents Chemother. 1980:17:470-3. CrossrefMedlineGoogle Scholar6. YUVICKERSZURAVLEFF VRJ. Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY127935) and eight other antipseudomonal antimicrobial agents (old and new). Antimicrob Agents Chemother. 1980;17:96-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Pittsburgh School of Medicine and Veterans Administration Medical Center Pittsburgh, Pennsylvania PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPeritonitis and Intraperitoneal AbscessesPeritonitis and Intraperitoneal AbscessesAntimicrobial resistance of enterococci in TurkeyMicrobiological and epidemiological studies of Enterococcus faecium resistant to amoxycillin in a university hospital in eastern FranceRisk Factors for Development of Vancomycin‐Resistant Enterococcal Bloodstream Infection in Patients with Cancer Who Are Colonized with Vancomycin‐Resistant EnterococciIn Vitro Assessment of Urinary Isolates of Ampicillin-Resistant EnterococciEffect of Antibiotic Therapy on the Density of Vancomycin-Resistant Enterococci in the Stool of Colonized PatientsThe influence of antibiotics on spread of vancomycin-resistant Enterococci: the potential role of selective use of antibiotics as a control measureRisk factors for enterococcal urinary tract infection and colonization in a rehabilitation facilityThe Challenge of Postoperative Infections: Does the Surgeon Make a Difference?Guideline for Prevention of Intravascular-Device–Related InfectionsGuideline for Prevention of Intravascular-Device-Related InfectionsColonization and infection with Enterococcus faecalis in intensive care units: the role of antimicrobial agentsDefinition of the role of enterococcus in intraabdominal infection: Analysis of a prospective randomized trialVancomycin Resistance in the Enterococcus: Relevance in PediatricsNew pathogens in pneumoniaHigh-Level Aminoglycoside Resistance Among Enterococci: Evaluation of an Agar Screen Susceptibility TestShort Communication: Effect of a Novel Parenteral Cephalosporin, E1077, on Normal Human Intestinal MicrofloraMicroorganisms and Diarrhea in Enterally Fed Intensive Care Unit PatientsTherapeutic effects of cefpirome (HR 810) on experimental mixed infections with enterococcus faecalis and escherichia coli in miceThe life and times of the EnterococcusLes cephalosporines dans le traitement des infections intra-abdominales: place de la ceririaxoneClinical implications of positive blood culturesNeonatal Septicaemia—Incidence, Etiology and Outcome A 6-year AnalysisCephalosporinsThe enterococci: Evidence of species-specific clinical and microbiologic heterogeneityNosocomial enterococcal infections: Association with use of third-generation cephalosporin antibioticsControlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patientsSpheroplast induction in clinical isolates of Serratia marcescens in the presence of Ca2+ or Mg2+Enterococcal urinary tract infections in a teaching hospitalThe Enterococcus: "Putting the Bug in Our Ears"STEPHEN A. HOFFMANN, M.D., ROBERT C. MOELLERING Jr., M.D.Bacteremia and fungemia in patients with neoplastic diseaseHigh-Dose Moxalactam in Gram-Negative Pneumonia: Efficacy and SafetyAntibacterial therapy in patients with malignanciesSingle agent cephalosporin prophylaxis for penetrating abdominal traumaThe EnterococcusEnterococcal bacteremia in two large community teaching hospitalsCefoperazone for empiric therapy in patients with impaired renal functionNEW ANTIBACTERIAL AGENTS AND THEIR USESDouble-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infectionsComparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patientsEffect of imipenem-cilastatin therapy on fecal floraAdverse Reactions and Interactions with Newer Cephalosporin and Cephamycin AntibioticsThird generation cephalosporin antibiotics in surgical practiceChapter 12. Antimicrobial Drugs – Clinical Problems and OpportunitiesInfluence of antibiotic prophylaxis on vaginal microfloraTicarcillin plus clavulanic acid in the treatment of patients with cancerTimentin versus moxalactam in the treatment of skin and soft tissue infectionsComparative toxicities of third-generation cephalosporinsEvaluation of aztreonam in the treatment of severe bacterial infectionsRandomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infectionsMoxalactam in nosocomial infections with Serratia marcescensCeftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremiaManagement in the febrile, neutropenic patient with cancer: Therapeutic considerationsColonization of hospitalized patients by Staphylococcus aureus, Staphylococcus epidermidis and enterococciBacterial synergism between the enterococcus and Escherichia coliGram-positive superinfections: A consequence of modern β-lactam chemotheraphyThe Cephalosporin Antibiotic Agents— III. Third-Generation CephalosporinsAntibiotic Management of Severe PeritonitisClinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organismsA review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogensGram-positive superinfections following beta-lactam chemotherapy: The significance of the enterococcusRespiratory superinfections after the use of third-generation cephem antibioticsComparison of the effectiveness of moxalactam and cefazolin in the prevention of infection in patients undergoing abdominal operationsA high incidence of bleeding is observed in a trial to determine whether addition of metronidazole is needed with latamoxef for prophylaxis in colorectal surgeryClinical significance of enterococci in woundsImipenem therapy of Pseudomonas aeruginosa and other serious bacterial infectionsCefotaxime Compared with Nafcillin Plus Tobramycin for Serious Bacterial Infections A Randomized, Double-Blind TrialCRAIG R. SMITH, M.D., RICHARD AMBINDER, M.D., JAMES J. LIPSKY, M.D., BRENT G. PETTY, M.D., ELLIOT ISRAEL, M.D., ROY LEVITT, M.D., E. DAVID MELLITS, SCD., LAURA ROCCO, R.N., M.S., JAMES LONGSTRETH, Ph.D., PAUL S. LIETMAN, M.D., Ph.DLes septicémies en réanimationMoxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patientsTimentin versus piperacillin or moxalactam in the therapy of acute bacterial infectionsMoxalactam Therapy of Serious; Pediatric InfectionsCephalosporin antibiotic agentsEnterococcal superinfection and colonization with aztreonam therapyPathophysiology, diagnosis, and treatment of abdominal abscessesMulticenter Clinical Trial of Cefoperazone Sodium in the United StatesAntimicrobial Therapy in Musculoskeletal SurgeryThe Great Cephalosporin WarsAZTREONAM COMPARED WITH GENTAMICIN FOR TREATMENT OF SERIOUS URINARY TRACT INFECTIONSEmpiric Therapy With Moxalactam Alone in Patients With BacteremiaNew Antibiotics.Recent Advances in Beta-lactam Antibiotics: A Symposium Held at the Soria Moria Conference Center, Oslo, Norway, February 24–25, 1984Imipenem versus moxalactam in the treatment of serious infectionsInteraction of cefotaxime and aminoglycosides against enterococci in vitroThe use of moxalactam in the treatment of serious infections due tu multi-resistant organismsComparison of moxalactam and gentamicin in the treatment of complicated urinary tract infectionsThird-Generation and Investigational Cephalosporins: II. Microbiologic Review and Clinical SummariesAn investigation of enterococcal bacteremiaUse of ceftazidime in the therapy of serious infections, including those due to multiresistant organismsMoxalactam/amikacin versus ticarcillin/amikacin in granulocytopenic patientsCeftriaxone therapy of bone and soft tissue infections in hospital and outpatient settingsProspective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infectionsTreatment of Acute Pneumonia in Infants and ChildrenTreatment of serious infections with moxalactamThe Cephalosporin AntibioticsCeftriaxone therapy of serious bacterial infections in adultsEnterococcal pneumoniaCefoperazone (Cefobid, Pfizer)The New Beta-Lactamase-Stable CephalosporinsHAROLD C. NEU, M.D.A Comparative Evaluation of Moxalactam: Antimicrobial Activity, Pharmacokinetics, Adverse Reactions, and Clinical EfficacyPathogenicity of enterococci outside of urinary tract and blood streamCLINICAL USES OF CEPHALOSPORINSRandomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adultsClinical evaluation of moxalactamClinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infectionsMANAGEMENT OF LIVER ABSCESSESMoxalactam (Moxam, Eli Lilly)In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibioticCHLAMYDIAL VULVOVAGINITIS IN A POSTMENOPAUSAL WOMANENTEROCOCCAL SENSITIVITY TO THIRD GENERATION CEPHALOSPORINS 1 June 1981Volume 94, Issue 6Page: 784-785KeywordsBacterial pathogensBacteroidesCerebrospinal fluidDrug therapyEnterobacteriaceaeHaemophilus influenzaePathogensPharmacokineticsPseudomonas aeruginosaSuperinfections Issue Published: 1 June 1981 PDF downloadLoading ...